期刊文献+

肝细胞癌围手术期抗复发治疗进展 被引量:3

原文传递
导出
摘要 肝细胞癌(以下简称肝癌)是全球第5大常见恶性肿瘤,列肿瘤致死原因第2位,全球每年肝癌新增病例85万,呈上升趋势[1-2]。外科手术为治愈肝癌惟一可能途径。随着手术技术的进步、围手术期管理水平的提高,高科技器械、设备以及新材料的应用,肝脏手术安全性大为提高。仍须看到的是,大量先进技术和新型抗癌药物被用于肝癌治疗,而治疗效果并未获得显著突破。
出处 《中国实用外科杂志》 CSCD 北大核心 2019年第12期1347-1350,共4页 Chinese Journal of Practical Surgery
关键词 肝细胞癌 抗复发治疗 hepatocellular carcinoma prevention of recurrence
  • 相关文献

参考文献3

二级参考文献13

  • 1Masatoshi Makuuchi,Norihiro Kokudo.Clinical practice guidelines for hepatocellular carcinoma:the first evidence based guidelines from Japan[J].World Journal of Gastroenterology,2006,12(5):828-829. 被引量:16
  • 2Josep M Llovet,Andrew Burroughs,Jordi Bruix.Hepatocellular carcinoma[J]. The Lancet . 2003 (9399)
  • 3Ann-Lii Cheng,Yoon-Koo Kang,Zhendong Chen,Chao-Jung Tsao,Shukui Qin,Jun Suk Kim,Rongcheng Luo,Jifeng Feng,Shenglong Ye,Tsai-Sheng Yang,Jianming Xu,Yan Sun,Houjie Liang,Jiwei Liu,Jiejun Wang,Won Young Tak,Hongming Pan,Karin Burock,Jessie Zou,Dimitris Voliotis,Zhongzhen Guan.Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial[J].Lancet Oncology.2009(1)
  • 4Sheung Tat Fan,Chung Mau Lo,Ronnie T. P. Poon,Chun Yeung,Chi Leung Liu,Wai Key Yuen,Chi Ming Lam,Kelvin K. C. Ng,See Ching Chan.Continuous Improvement of Survival Outcomes of Resection of Hepatocellular Carcinoma: A 20-Year Experience[J].Annals of Surgery.2011(4)
  • 5Roberto Gedaly,Paul Angulo,Jonathan Hundley,Michael F. Daily,Changguo Chen,B. Mark Evers.PKI-587 and Sorafenib Targeting PI3K/AKT/mTOR and Ras/Raf/MAPK Pathways Synergistically Inhibit HCC Cell Proliferation[J].Journal of Surgical Research.2012(2)
  • 6Luca Faloppi,Mario Scartozzi,Elena Maccaroni,Marzia Di Pietro Paolo,Rossana Berardi,Michela Del Prete,Stefano Cascinu.Evolving strategies for the treatment of hepatocellular carcinoma: From clinical-guided to molecularly-taylored therapeutic options[J].Cancer Treatment Reviews.2010(3)
  • 7Chun-Jen Liu,Po-Huang Lee,Deng-Yn Lin,Cheng-Chung Wu,Long-Bin Jeng,Pin-Wen Lin,King-Tong Mok,Wei-Chen Lee,Hong-Zen Yeh,Ming-Chih Ho,Sheng-Shun Yang,Ching-Chih Lee,Ming-Chin Yu,Rey-Heng Hu,Cheng-Yuan Peng,Kuan-Lang Lai,Stanley Shi-Chung Chang,Pei-Jer Chen.Heparanase inhibitor PI-88 as adjuvant therapy for hepatocellular carcinoma after curative resection: A randomized phase II trial for safety and optimal dosage[J].Journal of Hepatology.2009(5)
  • 8Alejandro Forner,Sasan Roayaie.Clinical research in hepatocellular carcinoma: Study design and endpoints[J].Journal of Hepatology.2009(5)
  • 9Hiroshi Ishii,Junji Yamamoto,Takaaki Ikari.Adjuvant treatments for resectable hepatocellular carcinoma[J].Journal of Hepato - Biliary - Pancreatic Surgery.2008(5)
  • 10Jonathan D Schwartz,Myron Schwartz,John Mandeli,Max Sung.Neoadjuvant and adjuvant therapy for resectable hepatocellular carcinoma: review of the randomised clinical trials[J].Lancet Oncology.2002(10)

共引文献41

同被引文献14

引证文献3

二级引证文献8

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部